University Hospital Essen Researchers Detail Research in Brain Metastasis (Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer...).
In: Cancer Weekly, 2023-12-26, S. 1322-1322
serialPeriodical
Zugriff:
A recent study conducted by researchers at University Hospital Essen in Germany examined the incidence and outcomes of brain metastasis in patients with advanced melanoma. The study found that despite the availability of effective systemic therapies, a significant number of patients developed brain metastases. The type of first-line therapy was found to impact the incidence and time to diagnosis of brain metastasis, as well as survival outcomes. The study concluded that first-line therapy with CTLA-4+PD-1 showed superior overall survival compared to PD-1 and BRAF+MEK therapies. However, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared to PD-1 in patients with wild-type BRAF. [Extracted from the article]
Copyright of Cancer Weekly is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
University Hospital Essen Researchers Detail Research in Brain Metastasis (Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer...).
|
---|---|
Zeitschrift: | Cancer Weekly, 2023-12-26, S. 1322-1322 |
Veröffentlichung: | 2023 |
Medientyp: | serialPeriodical |
ISSN: | 1071-7218 (print) |
Sonstiges: |
|